Genentech's Esbriet Granted Breakthrough Therapy Designation for uILD

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to Genentech’s Esbriet (pirfenidone) as a potential treatment for adults with unclassifiable interstitial lung disease (uILD) as the Roche subsidiary looks to expand its indications.